CureVac NV Ordinary Shares
CVAC: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$2.28 | Ztj | Kthpzxy |
CureVac Earnings: Early-Stage mRNA Pipeline Continues To Make Progress
CureVac is making progress across its early-stage mRNA pipeline. The company reported first-quarter revenue of EUR 7.1 million, of which revenue from its GSK collaboration agreement accounted for EUR 6.5 million. We maintain CureVac's fair value estimate of $15.40 per share, a no-moat rating, stable moat trend, and Extreme Morningstar Uncertainty Rating. The stock is trading at an attractive discount to our fair value estimate for long-term investors.